Ergoteles’s Crescent Biopharma CBIO Stock Holding History

Ergoteles’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,609	Closed	-$373K	–	1390
2021 Q2	$373K	Buy	+1,609	New	+$409K	0.01%	956

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ergoteles's CBIO Position: Q3 2021 in Review

Ergoteles sold out of Crescent Biopharma (CBIO) in Q3 2021, closing a stake of 1,609 shares — an estimated $373K sold.

Ergoteles first reported a position in CBIO in Q2 2021 and held it in 1 quarter. The position peaked at $373K in Q2 2021. 47 funds tracked by Wall St. Rank hold CBIO as of Q3 2021.

Ergoteles reported no remaining Crescent Biopharma position as of Q3 2021 after selling out during the quarter.
Ergoteles sold 1,609 Crescent Biopharma shares in Q3 2021, an estimated $373K.
Ergoteles first reported a position in Crescent Biopharma in Q2 2021 and held it in 1 quarter.
Ergoteles's Crescent Biopharma position peaked at $373K in Q2 2021.
47 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.